Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Treatment of primary insomnia

Jacques Montplaisir
CMAJ August 22, 2000 163 (4) 389-390;
Jacques Montplaisir
Sleep Disorders Centre HÔpital du Sacré-Cœur de Montréal Montreal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

A major problem with the meta-analysis by Anne Holbrook and colleagues of benzodiazepine use in the treatment of insomnia1 is that benzodiazepines were considered as a single medication; this class of drugs in fact consists of several compounds with marked differences in pharmacokinetics and side-effect profiles. Patients may be prescribed short-, intermediate- or long-acting compounds. Among other side effects, short-acting benzodiazepines cause daytime anxiety, amnesia and rebound insomnia upon withdrawal, whereas long-acting compounds cause residual sleepiness and cognitive impairments. Because the side effects differ so much from one compound to the next, those of benzodiazepines were not found to differ significantly from those of either a placebo or other insomnia treatments in the meta-analysis, which pooled studies investigating different benzodiazepines. They are nevertheless of prime importance for the clinician who has to choose a single hypnotic.

These side effects, especially the residual sleepiness and cognitive impairments, considerably limit the clinical use of benzodiazepines. As a result, several controlled studies have concluded that zopiclone should be recommended in ambulant or out-patient populations.2,3 The effects of hypnotics on breathing during sleep should also be considered. There are several indications that benzodiazepines depress respiration during sleep whereas zopiclone does not.4,5,6,7 This is important, especially in patients with chronic obstructive pulmonary disease, sleep apnea syndrome and upper airway resistance and, to a certain extent, in people who snore. Another clinical indication of zopiclone is its usefulness in the treatment of benzodiazepine dependency.8,9,10 Finally, a major advantage of zopiclone is that, unlike most benzodiazepines, it does not modify sleep architecture (most benzodiazepines reduce both slow-wave and REM sleep).6,11

I agree with Anne Holbrook and colleagues that nonpharmacological treatments are the treatment of choice for chronic primary insomnia.1 However, when comparing hypnotics, I believe that zopiclone has several advantages over each benzodiazepine taken separately.

References

  1. 1.↵
    Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000;162(2): 225-33.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Ponciano E, Freitas F, Camara J, Faria M, Barreto M, Hindmarch I. A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac patients. Int Clin Psychopharmacol 1990;5(Suppl 2):69-77.
    OpenUrlPubMed
  3. 3.↵
    Anderson AA. Zopiclone and nitrazepam: a multicenter placebo controlled comparative study of efficacy and tolerance in insomniac patients in general practice. Sleep 1987;10(Suppl 1):54-62.
    OpenUrl
  4. 4.↵
    Model DG. Nitrazam induced respiratory depression in chronic obstructive lung disease. Br J Dis Chest 1973;67:128-130.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Dolly FR, Block AJ. Effect of flurazepam on sleep-disordered breathing and nocturnal oxygen desaturation in asymptomatic patients. Am J Med 1984;73:239-43.
    OpenUrl
  6. 6.↵
    Muir JF, deFouilloy C, Broussier P, Locquet R, Maillard F. Comparative study of the effects of zopiclone and placebo on respiratory function in patients with chronic obstructive respiratory insufficiency. Int Clin Psychopharmacol 1990;5 (Suppl 2):85-94.
    OpenUrlPubMed
  7. 7.↵
    Lofaso F, Goldenberg F, Thebault C, Janus C, Harf A. Effect of zopiclone in sleep, night time ventilation and daytime vigilance in upper airway resistance syndrome. Eur Respir J 1997;10: 2573-7.
    OpenUrlAbstract
  8. 8.↵
    Shapiro CM, Sherman D, Peck DF. Withdrawal from benzodiazephines by initiating switching to zopiclone. Eur Psychiatry 1995;10(Suppl 3):145-51.
    OpenUrlCrossRef
  9. 9.↵
    Lemoine P, Ohayon MM. Is hypnotic withdrawal facilitated by the transitory use of a substitute drug? Prog Neuropsychopharmacol Biol Psychiatry 1997;21:111-24.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Pat-Horenczyk R, Hacohen D, Herer P, Lavie P. The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Psychopharmacol (Berl) 1998;140:450-7.
  11. 11.↵
    Gaillard JM. Benzodiazepines and gaba-ergic transmission. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 2nd ed. Philidelphia: WB Saunders; 1994. p. 349-54.
PreviousNext
Back to top

In this issue

CMAJ
Vol. 163, Issue 4
22 Aug 2000
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treatment of primary insomnia
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Treatment of primary insomnia
Jacques Montplaisir
CMAJ Aug 2000, 163 (4) 389-390;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Treatment of primary insomnia
Jacques Montplaisir
CMAJ Aug 2000, 163 (4) 389-390;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Virtual care and emergency department use
  • The denial of racism is racism itself
  • An expanded role for blood donor emerging pathogens surveillance
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire